

Metabolisch-Vaskuläres Syndrom und Diabetes im Alter

Welche rationalen Stellschrauben für Fitness, Resilienz und langes Leben bleiben uns?

M. Hanefeld

Literatur

- [1] <https://de.statista.com/statistik/daten/studie/273406/umfrage/entwicklung-der-lebenserwartung-bei-geburt-in-deutschland-nach-geschlecht/>, abgerufen am 11.02.2022
- [2] Baumgart, Matthew; Snyder, Heather M.; Carrillo, Maria C.; Fazio, Sam; Kim, Hye; Johns, Harry (2015): Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. In: *Alzheimer's & dementia : the journal of the Alzheimer's Association* 11 (6), S. 718–726. DOI: 10.1016/j.jalz.2015.05.016.
- [3] Chiang, Jason I.; Hanlon, Peter; Li, Tsai-Chung; Jani, Bhautesh Dinesh; Manski-Nankervis, Jo-Anne; Furler, John et al. (2020): Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohorts. In: *PLoS medicine* 17 (5), e1003094. DOI: 10.1371/journal.pmed.1003094.
- [4] Hanefeld, Markolf; Koehler, Carsta; Gallo, Silvina; Benke, Inge; Ott, Petra (2007): Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. In: *Cardiovascular diabetology* 6, S. 13. DOI: 10.1186/1475-2840-6-13.
- [5] Nauck, Michael; Weinstock, Ruth S.; Umpierrez, Guillermo E.; Guerci, Bruno; Skrivaneck, Zachary; Milicevic, Zvonko (2014): Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). In: *Diabetes care* 37 (8), S. 2149–2158. DOI: 10.2337/dc13-2761.
- [6] Galiuto, Leonarda; Patrono, Carlo (2021): Physical activity and mortality reduction: is volume or intensity the key variable? In: *European heart journal* 42 (7), S. 730–731. DOI: 10.1093/eurheartj/ehaa1074.
- [7] Landré, Benjamin; Fayosse, Aurore; Ben Hassen, Céline; Machado-Fragua, Marcos D.; Dumurgier, Julien; Kivimaki, Mika et al. (2021): Terminal decline in objective and self-reported measures of motor function before death: 10 year follow-up of Whitehall II cohort study. In: *BMJ* 374, n1743. DOI: 10.1136/bmj.n1743.
- [8] Lee, I. M.; Hsieh, C. C.; Paffenbarger, R. S., JR (1995): Exercise intensity and longevity in men. The Harvard Alumni Health Study. In: *JAMA* 273 (15), S. 1179–1184.
- [9] Bilz, Alfred: *Bilz' Goldene Lebensregeln*, 2. Auflage, Reprint der Ausgabe Dresden, Radebeul, Leipzig, Bilz, 1907 / mit einem Kommentar von Josef Rudolf Noswitz ... In Zusammenarbeit mit dem Bilz-Bund für Naturheilkunde e.V. – Weilrod/Taunus: Unikat-Verl., 1996.
- [10] Tuomilehto, J.; Rastenyte, D.; Birkenhäger, W. H.; Thijs, L.; Antikainen, R.; Bulpitt, C. J. et al. (1999): Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. In: *The New England journal of medicine* 340 (9), S. 677–684. DOI: 10.1056/NEJM199903043400902.
- [11] Cosentino, Francesco; Grant, Peter J.; Aboyans, Victor; Bailey, Clifford J.; Ceriello, Antonio; Delgado, Victoria et al. (2020): 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. In: *European heart journal* 41 (2), S. 255–323. DOI: 10.1093/eurheartj/ehz486.
- [12] LaRosa, John C.; Grundy, Scott M.; Waters, David D.; Shear, Charles; Barter, Philip; Fruchart, Jean-Charles et al. (2005): Intensive lipid lowering with atorvastatin in patients with stable coronary disease. In: *The New England journal of medicine* 352 (14), S. 1425–1435. DOI: 10.1056/NEJMoa050461.
- [13] Ridker, Paul M.; Danielson, Eleanor; Fonseca, Francisco A. H.; Genest, Jacques; Gotto, Antonio M., JR; Kastelein, John J. P. et al. (2008): Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. In: *The New England journal of medicine* 359 (21), S. 2195–2207. DOI: 10.1056/NEJMoa0807646.

- [14] Ramos, Rafael; Comas-Cufí, Marc; Martí-Lluch, Ruth; Balló, Elisabeth; Ponjoan, Anna; Alves-Cabratosa, Lia et al. (2018): Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. In: *BMJ* 362, k3359. DOI: 10.1136/bmj.k3359.
- [15] Kaptoge, Stephen; Di Angelantonio, Emanuele; Lowe, Gordon; Pepys, Mark B.; Thompson, Simon G.; Collins, Rory; Danesh, John (2010): C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. In: *Lancet* (London, England) 375 (9709), S. 132–140. DOI: 10.1016/S0140-6736(09)61717-7.
- [16] Physicians Health
- [17] Women's Health
- [18] Ridker, Paul M.; Everett, Brendan M.; Thuren, Tom; MacFadyen, Jean G.; Chang, William H.; Ballantyne, Christie et al. (2017): Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. In: *The New England journal of medicine* 377 (12), S. 1119–1131. DOI: 10.1056/NEJMoa1707914.
- [19] Ridker, P. M. (2001): High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. In: *Circulation* 103 (13), S. 1813–1818. DOI: 10.1161/01.cir.103.13.1813.
- [20] Ridker, Paul M.; Danielson, Eleanor; Fonseca, Francisco A. H.; Genest, Jacques; Gotto, Antonio M., JR; Kastelein, John J. P. et al. (2018): Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. In: *The New England journal of medicine* 359 (21), S. 2195–2207. DOI: 10.1056/NEJMoa0807646.
- [21] Ridker, Paul M. (2009): The JUPITER trial: results, controversies, and implications for prevention. In: *Circulation. Cardiovascular quality and outcomes* 2 (3), S. 279–285. DOI: 10.1161/CIRCOUTCOMES.109.868299.
- [22] ARIC Study
- [23] Sinclair, David: *Das Ende des Alterns: Die revolutionäre Medizin von Morgen*, DuMont 2020.
- [24] Gerstein, Hertz C. et al. "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial." *The lancet. Diabetes & endocrinology* (2020): n. pag.